高盛刚给心玮医疗买入评级，第二天就大涨的心玮真有翻倍可能吗？

江瀚的视野2021-09-30

根据智通财经的报道，高盛发布研究报告称，首予心玮医疗-B(06609)“买入”评级，目标价218港元，估计其今明两年收入分别为9000万及2.79亿元人民币，当中已考虑到2026年全国带量采购会覆盖所有急性缺血性脑卒中机械取栓术治疗的产品线，而栓塞弹簧圈为2023年。报告中称，公司为中国神经介入医疗器械市场的先行者，产品组合包括急性缺血性脑卒中、出血性脑卒中及颅内动脉狭窄的产品。借着具成本效益的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

风飘悠然
2021-09-30
风飘悠然
加油！看好心玮医疗！
赚钱缴费
2021-09-30
赚钱缴费
楼主应该是被深套了

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2171218935?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/8e87285f5f61644eaba65898e6ccf2bf","is_english":false,"pubTime":"2021-09-30 06:45","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2171218935","market":"hk","top_or_hot":-1,"title":"高盛刚给心玮医疗买入评级，第二天就大涨的心玮真有翻倍可能吗？","media":"江瀚的视野","content":"<div>\n<p>根据智通财经的报道，高盛发布研究报告称，首予心玮医疗-B(06609)“买入”评级，目标价218港元，估计其今明两年收入分别为9000万及2.79亿元人民币，当中已考虑到2026年全国带量采购会覆盖所有急性缺血性脑卒中机械取栓术治疗的产品线，而栓塞弹簧圈为2023年。报告中称，公司为中国神经介入医疗器械市场的先行者，产品组合包括急性缺血性脑卒中、出血性脑卒中及颅内动脉狭窄的产品。借着具成本效益的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2021093006483779f7118b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛刚给心玮医疗买入评级，第二天就大涨的心玮真有翻倍可能吗？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛刚给心玮医疗买入评级，第二天就大涨的心玮真有翻倍可能吗？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-30 06:45 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2021093006483779f7118b&s=b><strong>江瀚的视野</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>根据智通财经的报道，高盛发布研究报告称，首予心玮医疗-B(06609)“买入”评级，目标价218港元，估计其今明两年收入分别为9000万及2.79亿元人民币，当中已考虑到2026年全国带量采购会覆盖所有急性缺血性脑卒中机械取栓术治疗的产品线，而栓塞弹簧圈为2023年。报告中称，公司为中国神经介入医疗器械市场的先行者，产品组合包括急性缺血性脑卒中、出血性脑卒中及颅内动脉狭窄的产品。借着具成本效益的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2021093006483779f7118b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06609","symbol_name":"心玮医疗-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2021093006483779f7118b&s=b","article_id":"2171218935","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/8e87285f5f61644eaba65898e6ccf2bf"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2021093006483779f7118b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2171218935","pubTimestamp":1632955500,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"消息一出，心玮医疗立马大涨，截至2021年9月28日收盘，心玮医疗报113.9港元每股，大涨13.79%，大家不禁想问心玮医疗真的拥有翻倍股的潜质吗？我们到底该怎么看高盛给心玮医疗的评级呢？所以，当高盛给出了一个基本上翻番的评价之后，大概率其他的投资银行也会跟进，甚至机构投资者会直接下场，这就是大涨的核心逻辑。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"06609":"心玮医疗-B"},"translate_title":"Goldman Sachs just gave Xinwei Medical a buying rating, and is it really possible for Xinwei, which rose sharply the next day, to double?","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06609":1},"content_text":"根据智通财经的报道，高盛发布研究报告称，首予心玮医疗-B(06609)“买入”评级，目标价218港元，估计其今明两年收入分别为9000万及2.79亿元人民币，当中已考虑到2026年全国带量采购会覆盖所有急性缺血性脑卒中机械取栓术治疗的产品线，而栓塞弹簧圈为2023年。报告中称，公司为中国神经介入医疗器械市场的先行者，产品组合包括急性缺血性脑卒中、出血性脑卒中及颅内动脉狭窄的产品。借着具成本效益的跨国公司替代品，公司有望受惠于进口替代，并抓住急性缺血性脑卒中相关机械取栓术日渐普及的增长机会。消息一出，心玮医疗立马大涨，截至2021年9月28日收盘，心玮医疗报113.9港元每股，大涨13.79%，大家不禁想问心玮医疗真的拥有翻倍股的潜质吗？我们到底该怎么看高盛给心玮医疗的评级呢？首先，作为全世界最顶尖的投资银行，高盛在资本市场上其实有着说一不二的市场地位，所以在这样的情况之下，高盛给任何一家新上市的公司以评级往往都被市场认为是非常重要的事情，所以当高盛给心玮医疗给出了一个买入评级，而且给出了一个几乎翻倍的目标价的时候，很多人都会认为这是高盛对于心玮医疗的认可，自然会带动资本市场的情绪，让资本市场给心玮医疗投下了自己的信任票。其次，我们再来看心玮医疗本身，在心玮医疗上市的时候，我们之前就曾经反复说过这件事，对于心玮医疗这样的公司，他所拥有的特殊属性让这家公司实际上是一个在垂直赛道上具有较强市场竞争力的独角兽。而且其以研发为驱动的特殊优势可以帮助心玮医疗在神经介入医疗器械这个赛道上有着不错的市场表现。与此同时，心玮医疗是一个研发和市场推广同时较强的公司，大量的【在研管线】和已经得到商业化的产品之间处于一个相辅相成的关系。只要心玮医疗在这方面能够保持较为稳健的发展的话，必然能够给资本市场以一个不错的基本面表现。第三，从长期市场发展的角度来看，资本市场给予一家新上市公司的评级往往是非常重要的，因为良好的开端是成功的一半，由高盛给心玮医疗下了一个几乎定调的评级，之后，其他的投资银行也就有可能进一步跟进，从而在市场上形成一个比较看好的态势，所以这才是当前资本市场有明显反应的原因所在。所以，当高盛给出了一个基本上翻番的评价之后，大概率其他的投资银行也会跟进，甚至机构投资者会直接下场，这就是大涨的核心逻辑。当前对于心玮医疗这家公司来说，最核心的任务应该是进一步的将自己的研发做好，将产品的推广落到实处，逐步实现国产替代，给资本市场以足够好的业绩表现，从而让高盛的这种估值能够落到实处，这才是心玮医疗当前最需要做的事情。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":865879635,"gmtCreate":1632970716942,"gmtModify":1632970716942,"author":{"id":"4087690994810380","authorId":"4087690994810380","name":"风飘悠然","avatar":"https://static.tigerbbs.com/36494b2bad0df1796be11e610414c16e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087690994810380","idStr":"4087690994810380"},"htmlText":"加油！看好心玮医疗！","listText":"加油！看好心玮医疗！","text":"加油！看好心玮医疗！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/865879635","repostId":2171218935,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":865145841,"gmtCreate":1632963776053,"gmtModify":1632963776053,"author":{"id":"3573376057610290","authorId":"3573376057610290","name":"赚钱缴费","avatar":"https://static.tigerbbs.com/3ee62644cae45cae9867cae29a1644cd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3573376057610290","idStr":"3573376057610290"},"htmlText":"楼主应该是被深套了","listText":"楼主应该是被深套了","text":"楼主应该是被深套了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/865145841","repostId":2171218935,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":12,"commentSize":2,"repostSize":0,"favoriteSize":2,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2171218935"}